Prothena Corp Public (PRTA) Depreciation & Amortization (CF) (2012 - 2026)
Prothena Corp Public (PRTA) recorded quarterly Depreciation & Amortization (CF) of $184000.0 in Q1 2026, down 15.6% quarter-over-quarter from $218000.0 in Q4 2025, and down 17.49% on a YoY basis from $223000.0 in Q1 2025.
Prothena Corp Public (PRTA) Depreciation & Amortization (CF) (2012 - 2026) Analysis & Trends
Prothena Corp Public's Depreciation & Amortization (CF) history runs 15 years deep, the most recent figure standing at $184000.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 17.49% year-over-year to $184000.0; the TTM figure through Mar 2026 stood at $856000.0 (down 4.99% YoY), while the FY2025 annual figure was $895000.0, changed 0.22% from the prior year.
- Depreciation & Amortization (CF) was $184000.0 for Q1 2026 at Prothena Corp Public, down from $218000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $276000.0 in Q4 2023 to a low of $182000.0 in Q1 2022.
- Historically, Depreciation & Amortization (CF) has averaged $214352.9 across 5 years, with a median of $221000.0 in 2024.
- The sharpest annual moves came in 2022 and 2023: Depreciation & Amortization (CF) tumbled 40.13% in 2022, then surged 40.82% in 2023.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $196000.0 in 2022, then soared by 40.82% to $276000.0 in 2023, then slipped by 19.93% to $221000.0 in 2024, then dropped by 1.36% to $218000.0 in 2025, then slipped by 15.6% to $184000.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $184000.0 (Q1 2026), $218000.0 (Q4 2025), and $229000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1,395.22 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 429,663.65 |
| 10 | Prothena Corp Public | 479.08 Mn | 149.61 Mn | - | 184,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 184,000.00 |
| Mar 31, 2026 | 184,000.00 |
| Dec 31, 2025 | 218,000.00 |
| Dec 31, 2025 | 218,000.00 |
| Sep 30, 2025 | 229,000.00 |
| Sep 30, 2025 | 229,000.00 |
| Jun 30, 2025 | 225,000.00 |
| Jun 30, 2025 | 225,000.00 |
| Mar 31, 2025 | 223,000.00 |
| Mar 31, 2025 | 223,000.00 |
| Dec 31, 2024 | 221,000.00 |
| Dec 31, 2024 | 221,000.00 |
| Sep 30, 2024 | 226,000.00 |
| Sep 30, 2024 | 226,000.00 |
| Jun 30, 2024 | 231,000.00 |
| Jun 30, 2024 | 231,000.00 |
| Mar 31, 2024 | 215,000.00 |
| Mar 31, 2024 | 215,000.00 |
| Dec 31, 2023 | 276,000.00 |
| Dec 31, 2023 | 276,000.00 |